The therapeutic landscape in metastatic RCC has changed considerably over recent decades and immune checkpoint inhibitors, alone or in combination with VEGF targeting agents, are now accepted first-line therapies [3,4,5]. Here, VEGFA is linked to renal cell carcinoma.